ストックスクリーナーアプリを入手
3.94
5.52%
-0.23
前日終値:
$4.17
開ける：
$4.255
24時間の取引高:
2,761
Relative Volume:
0.54
時価総額：
$214.01M
収益：
-
当期純損益:
-
株価収益率:
-5.3671
EPS:
-0.7341
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.77%
1か月 パフォーマンス:
-9.07%
6か月 パフォーマンス:
+6.92%
1年 パフォーマンス:
-33.33%
1日の値動き範囲:
$4.1802
$4.28
1週間の範囲:
$3.93
$4.49
52週間の値動き範囲:
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.28 | 208.51M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.28 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
474.00 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.47 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.63 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.56 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-12-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | アップグレード | Stifel | Hold → Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Underperform |
| 2020-05-13 | ダウングレード | Kepler | Buy → Reduce |
| 2020-05-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-05-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 繰り返されました | B. Riley FBR | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-04-24 | 開始されました | SVB Leerink | Outperform |
| 2019-04-22 | 開始されました | Barclays | Overweight |
すべてを表示
Genfit Adr (GNFT) 最新ニュース
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs See Mixed Results With Modest Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr (GNFT) 財務データ
Genfit Adr (GNFT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.01%
0.08%
大文字化:
|
ボリューム (24 時間):